Kristina Luthman - Oncopeptides Founder
| ONCO Stock | SEK 1.66 0.15 9.93% |
Insider
Kristina Luthman is Founder of Oncopeptides AB
| Phone | 46 86 15 20 40 |
| Web | https://www.oncopeptides.com/sv |
Oncopeptides Management Efficiency
The company has return on total asset (ROA) of (0.6651) % which means that it has lost $0.6651 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.2916) %, meaning that it generated substantial loss on money invested by shareholders. Oncopeptides' management efficiency ratios could be used to measure how well Oncopeptides manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jan Mattsson | BioArctic AB | 63 | |
| Ignacio GarciaRibas | Cantargia AB | N/A | |
| Adnan Deronic | Cantargia AB | N/A | |
| Klaus Sindahl | Hansa Biopharma AB | N/A | |
| Nina Valkama | Cantargia AB | N/A | |
| Emanuel Bjrne | Hansa Biopharma AB | 50 | |
| Peter Madsen | Cantargia AB | N/A | |
| Oskar Bosson | BioArctic AB | 47 | |
| Susanne Lagerlund | Cantargia AB | N/A | |
| Sren MSc | Hansa Biopharma AB | 58 | |
| Johan MSc | Sinch AB | 50 | |
| Dominique Tersago | Cantargia AB | 61 | |
| Katja Margell | Hansa Biopharma AB | N/A | |
| Ed OHara | Sinch AB | 59 | |
| Marcuss | Cantargia AB | N/A | |
| Anne Lanner | Hansa Biopharma AB | 54 | |
| Gunilla Osswald | BioArctic AB | 62 | |
| Johanna Christensen | Cantargia AB | N/A | |
| Christina Raaschou | Sinch AB | 46 | |
| Will Conway | Sinch AB | 38 | |
| Pr Lannfelt | BioArctic AB | 74 | |
Management Performance
| Return On Equity | -1.29 | |||
| Return On Asset | -0.67 |
Oncopeptides AB Leadership Team
Elected by the shareholders, the Oncopeptides' board of directors comprises two types of representatives: Oncopeptides inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncopeptides. The board's role is to monitor Oncopeptides' management team and ensure that shareholders' interests are well served. Oncopeptides' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncopeptides' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Annika MBA, Interim Officer | ||
| Kristina Luthman, Founder | ||
| Linda Holmstrom, Director Relations | ||
| Peter Nygren, Founder | ||
| Pr MD, Founder | ||
| Jakob Lic, Chief Officer | ||
| MSc MD, Founder | ||
| MSc MSc, COO MD |
Oncopeptides Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oncopeptides a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.29 | |||
| Return On Asset | -0.67 | |||
| Operating Margin | 49.84 % | |||
| Current Valuation | 776.19 M | |||
| Shares Outstanding | 90.37 M | |||
| Shares Owned By Insiders | 10.76 % | |||
| Shares Owned By Institutions | 47.54 % | |||
| Price To Book | 2.96 X | |||
| Price To Sales | 34.76 X | |||
| Revenue | 118.3 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Oncopeptides Stock Analysis
When running Oncopeptides' price analysis, check to measure Oncopeptides' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncopeptides is operating at the current time. Most of Oncopeptides' value examination focuses on studying past and present price action to predict the probability of Oncopeptides' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncopeptides' price. Additionally, you may evaluate how the addition of Oncopeptides to your portfolios can decrease your overall portfolio volatility.